OpenAlex
PricingAboutJobs
Log inGet started
Author

R Comenzo

Observed names: Comenzo, RL, Rl Comenzo
OpenAlex ID: A5074859256

Prospective Evaluation of the Utility of the Serum Free Light Chain Assay (FLC), Clonal Ig VL Gene Identification and Troponin I Levels in a Phase II Trial of Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic AL Amyloidosis
2004 · Rl Comenzo, P. Zhou, et al. · CRC Press eBooks · 2
Subcutaneous Daratumumab (Dara) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients With Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival (OS) and Final Major Organ Deterioration Progression-Free Survival Results From the Phase 3 Andromeda
2025 · Carpinteiro, A, Kastritis, E, et al. · UCL Discovery (University College London)
Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic Al Amyloidosis: Interim Report of a Phase II Trial
2004 · P Zhou, M Fleisher, et al. · CRC Press eBooks
Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic AL Amyloidosis: Interim Report of a Phase II Trial
2004 · Rl Comenzo, P. Zhou, et al. · CRC Press eBooks
Works count: 4
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security